Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;36(1):e72.
doi: 10.3802/jgo.2025.36.e72.

Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

Sung Jong Lee #  1 , Ji Geun Yoo #  2 , Jin Hwi Kim  3 , Jeong-Yeol Park  4 , Jung-Yun Lee  5 , Yoo-Young Lee  6 , Dong Hoon Suh  7
Affiliations
Review

Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

Sung Jong Lee et al. J Gynecol Oncol. 2025 Jan.

Abstract

This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.

Keywords: Gynecologic Neoplasms; Immunoconjugates; Immunotherapy; Molecular Targeted Therapy; Poly(ADP-Ribose) Polymerase Inhibitor.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

    1. Schmeler KM, Frumovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol. 2011;120:321–325. - PMC - PubMed
    1. Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med. 2024;390:819–829. - PubMed
    1. Takekuma M. Challenges and perspectives on less invasive surgery for early-stage cervical cancer: a critical analysis of the SHAPE trial and its implications. J Gynecol Oncol. 2024;35:e48. - PMC - PubMed
    1. Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, et al. Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: an exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial. Int J Gynecol Cancer. 2025;35:100001. - PubMed
    1. Ramirez PT. Minimally invasive surgery for simple hysterectomy in early-stage cervical cancer: ‘SHAPing’ a path forward. Int J Gynecol Cancer. 2025;35:101619. - PubMed